Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | Hello TELLOMAK: new trial for T-cell lymphoma

Pierluigi Porcu • 19 Jul 2019
ICML 2019
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Peripheral T-Cell Lymphoma Rare Diseases T-Cell Lymphoma IPH4102
TELLOMAK

Pierluigi Porcu, MD, Sidney Kimmel Cancer Center – Jefferson Health, Philadelphia, PA, discusses the current open-label, multicohort, multi-center, international Phase II TELLOMAK trial (NCT03902184), evaluating the anti-KIR3DL2 agent IPH4102 alone or with chemotherapy in advanced T-cell lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Pierluigi Porcu

HRQoL in patients with R/R CTCL treated with lacutamab in the TELLOMAK trial
5:21
HRQoL in patients with R/R CTCL treated with lacutamab in the TELLOMAK trial
Pierluigi Porcu • 9 Dec 2024
The current standard of care for CTCL
3:46
The current standard of care for CTCL
Pierluigi Porcu • 9 Dec 2024
Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD
2:49
Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD
Pierluigi Porcu • 16 Jun 2023
The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges
3:00
The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges
Pierluigi Porcu • 16 Jun 2023

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Pierluigi Porcu • 7 Dec 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Pierluigi Porcu • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Pierluigi Porcu • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Pierluigi Porcu • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals